• CUBIK
(GECP 19/01)
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study.
NCT04223596
• THOMAS
(GECP 17/04
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations.
NCT03496766
• BOOSTER
(ETOP 10-16)
A Randomised Phase II Trial of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M.
NCT03133546
• ABC-Lung
(ETOP 15-19)
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance.
NCT04245085
• STEREO
(ETOP 17-20)
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer.
NCT04908956
• AMAZE-lung
(ETOP 18-21)
A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI.
NCT05601973
• ADEPPT
(ETOP 22-22)
A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status.
NCT05673187
• PEBEL
(GECP 16/06)
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting.
NCT03293680
• NVALT
(NVALT-15)
Phase II study with BIBF1120, an oral fibroblast growth factor 1 inhibitor, as second-line treatment in patients with non-small cell lung cancer and fibroblast growth factor receptor 1 gene amplification (NVALT-15).
• ALERT-Lung
(ETOP 12-17)
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC.
NCT03445000